Leila Haddad
Hospital Italiano de Buenos Aires
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Leila Haddad.
Liver International | 2017
Julieta Trinks; Nao Nishida; María Laura Hulaniuk; Mariela Caputo; Takayo Tsuchiura; Sebastián Marciano; Leila Haddad; Jorgelina L. Blejer; Sonia Bartoli; Beatriz Ameigeiras; S. Frias; Cecilia Vistarini; Fabiana Heinrich; Carlos Remondegui; Susana Ceballos; Gustavo Echenique; Miguel Charre Samman; Claudia D'Amico; Amalia Rojas; Alfredo P. Martínez; Ezequiel Ridruejo; Roberto J Fernández; Leandro Burgos Pratx; Horacio J Salamone; Félix Nuñez; Omar Galdame; Adrián Gadano; Daniel Corach; Masaya Sugiyama; Diego Flichman
HBV infection exhibits geographical variation in its distribution in South America. While HBV rates are low in central Argentina, the north‐western region exhibits intermediate HBV rates. Unfortunately, the reasons that could explain this difference are still unknown.
Journal of Medical Virology | 2017
Manuel Mendizabal; Leila Haddad; Patricia E. Gallardo; Alejandro Ferrada; Alejandro Soza; Raúl Adrover; Edmundo Aravena; Juan Pablo Roblero; Jhon Prieto; Claudia Vujacich; Gustavo Romero; Alberto Muñoz; Margarita Anders; Nelia Hernández; Daniel Coccozella; Fernando Gruz; Maria V. Reggiardo; Andrés Ruf; Adriana Varón; Mariano Cartier; Roberto Pérez Ravier; Ezequiel Ridruejo; Mirta Peralta; Daniel Poncino; Julio Vorobioff; Gabriel Aballay Soteras; Marcelo Silva
Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real‐clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real‐world setting. We analyzed a cohort of patients with genotype 1 infection treated with OBV/PTV/r/DSV ± RBV. Data on demographics, clinical features, safety, and virological response were retrospectively collected from 21 centers in Latin America. A total of 96 patients received OBV/PTV/r/DSV, associated with RBV in 68% of the cases. Most were genotype 1b (80%), 56 (58%) had cirrhosis, and 45 (47%) failed prior HCV treatment. Adverse events occurred in 62% of patients. The most common adverse events were pruritus (21%), hyperbilirubinemia (17%), and asthenia (17%). Five patients discontinued therapy prematurely due to hepatic decompensation, three of them were Child‐Pugh B at baseline and one patient died due to multi‐organ failure. Follow up HCV‐RNA 12 weeks after completion of therapy was evaluated in all the patients and sustained virologic response rate was 97%. No virologic breakthrough was detected. Our study confirms that OBV/PTV/r/DSV treatment is highly effective in patients with chronic HCV without cirrhosis or with Child‐Pugh A cirrhosis in non‐European populations. Adverse events were often mild and rarely led to treatment discontinuation except for patients with Child‐Pugh B cirrhosis or with previous history of hepatic decompensation. These results can support the development of public strategies to expand the access of OBV/PTV/r + DSV and other DAAs combinations in order to reduce the burden of HCV infection in our region.
Journal of Medical Virology | 2018
Sebastián Marciano; Leila Haddad; Maria V. Reggiardo; Mirta Peralta; Cecilia Vistarini; Mónica Marino; Valeria Descalzi; Claudia D'Amico; Sebastián Figueroa Escuti; Luis Gaite; Roberto Pérez Ravier; Cristina Longo; Silvia Borzi; Omar Galdame; Fernando Bessone; Hugo Fainboim; S. Frias; Mariano Cartier; Adrián Gadano
We report the first real‐world prospective multicenter cohort study that evaluated the effectiveness and safety of original or generic sofosbuvir‐based regimens in patients with chronic hepatitis C in Latin America. The main endpoints were assessment of sustained virological response and serious adverse events rates. A total of 321 patients with chronic hepatitis C treated with the following regimens were included: sofosbuvir plus daclatasvir for 12 (n = 34) or 24 (n = 135) weeks, sofosbuvir plus daclatasvir plus ribavirin for 12 (n = 84) or 24 (n = 56) weeks, or sofosbuvir plus ribavirin for 12 (n = 8) or 24 (n = 2) weeks. Patients received either original sofosbuvir (Sovaldi®, Gilead Sciences, n = 135) or generic sofosbuvir (Probirase®, Laboratorios RICHMOND, n = 184) which were randomly assigned by the National Ministry of Health. Overall, 292 (91%) patients had cirrhosis, 136 (42%) were treatment experienced, and 240 (75%) genotype 1. The overall sustained virological response was 90% (95% CI 86‐93%); 91% (95% CI 84‐95%) in patients who received Sovaldi®, and 89% (95% CI 84‐93%) in patients who received Probirase®. Anemia was the most common adverse event and was reported in 52 (17%) patients. Bacterial infection, gastrointestinal bleeding, worsening of ascites or encephalopathy occurred in less than 5% of the patients. During the study, seven (2%) patients died, four of whom died of cirrhosis‐related complications. In summary, we observed similar sustained virological response rates than prior studies, both in patients who received Sovaldi® or Probirase®. Serious adverse events were infrequent, in line with prior studies that included patients with cirrhosis treated with protease‐inhibitor‐free regimes.
Transplantation Proceedings | 2018
Leila Haddad; Sebastián Marciano; M. Cleres; A. Zerega; F. Piñero; F. Orozco; G. Braslavsky; M. Mendizabal; G. Gondolesi; O. Gil; M. Silva; R. Mastai; O. Imventarza; Valeria Descalzi; Adrián Gadano
INTRODUCTION There is a lack of information regarding outcomes after liver transplant in Latin America. OBJECTIVES This study sought to describe outcomes after liver transplant in adult patients from Argentina. METHODS We performed an ambispective cohort study of adult patients transplanted between June 2010 and October 2012 in 6 centers from Argentina. Only patients who survived after the first 48 hours postransplantation were included. Pretransplantation and posttransplantation data were collected. RESULTS A total of 200 patients were included in the study. Median age at time of transplant was 50 (interquartile range [IQR] 26 to 54) years. In total, 173 (86%) patients had cirrhosis, and the most frequent etiology in these patients was hepatitis C (32%). A total of 35 (17%) patients were transplanted with hepatocellular carcinoma. In patients with cirrhosis, the median Model for End-Stage Liver Disease (MELD) score at time of liver transplant was 25 (IQR 19 to 30). Median time on the waiting list for elective patients was 101 (IQR 27 to 295) days, and 3 (IQR 2 to 4) days for urgent patients. Almost 40% of the patients were readmitted during the first 6 months after liver transplant. Acute rejection occurred in 27% of the patients. Biliary and vascular complications were reported in 39 (19%) and 19 (9%) patients, respectively. Renal failure, diabetes, and dyslipidemia were present in 40 (26%), 87 (57%), and 77 (50%) at 2 years, respectively. CONCLUSIONS We believe the information contained in this article might be of value for reviewing current practices and developing local policies.
Revista Portuguesa De Pneumologia | 2018
Sebastián Marciano; Leila Haddad; S.M. Borzi; C. D’Amico; L.A. Gaite; M.V. Aubone; M.E. Sirotinsky; N. Ratusnu; M.S. Frola; M.C. Aparicio; B. Ríos; M.N. Anselmo; R. Hansen; S. De Filippi; C. García Dans; L. de Labra; M.A. Peche; T.M. Strella; M. Ibáñez Duran; M.B. García Rosales; M. Dirchwolf; O.A. Galdame; Adrián Gadano
AIMS To estimate the number of patients that have access to treatment of hepatitis C with direct-acting antivirals in Argentina and evaluate the factors associated with the lack of access. MATERIALS AND METHODS A cross-sectional cohort study was conducted that included all the consecutive prescriptions of direct-acting antivirals issued at health centers that participated in the ECHOTM telemedicine project directed by the Hospital Italiano de Buenos Aires, within the time frame of January 2016 and February 2017. RESULTS A total of 143 treatment prescriptions were included and overall access was 70% (95% CI 62-77%). The only independent factor associated with a lack of treatment access was coverage by a public healthcare system (OR 4.98 [95% CI 2.05- 12.09]). CONCLUSION Patients with hepatitis C that were covered by a public healthcare system had a 4 times higher chance of not having access to treatment with direct-acting antivirals than patients covered by other healthcare systems (private insurance or the social welfare system).
Annals of Hepatology | 2014
Sebastián Marciano; Leila Haddad; Alfredo P. Martínez; María L. Posadas; Federico Piñero; Gonzalo J. Mora; Laura N. Guerrero; Ezequiel Ridruejo; Oscar G. Mandó; Diego H. Giunta; Adrián Gadano
Journal of Medical Virology | 2017
Sebastián Marciano; Leila Haddad; Fernando Plazzotta; Ezequiel Mauro; Sergio Terraza; Sanjeev Arora; Karla Thornton; B. Ríos; Carlos García Dans; Natalia Ratusnu; Liliana Calanni; José Allevato; M.E. Sirotinsky; Marcos Pedrosa; Adrián Gadano
Hepatology International | 2018
Sebastián Marciano; Melisa Dirchwolf; Carla S. Bermudez; Natalia Sobenko; Leila Haddad; Federico Genre Bert; Laura Barcán; Astrid Smud; María Lourdes Posadas-Martínez; Diego Giunta; Adrián Gadano
Revista de Gastroenterología de México (English Edition) | 2018
Sebastián Marciano; Leila Haddad; S.M. Borzi; C. D’Amico; L.A. Gaite; M.V. Aubone; M.E. Sirotinsky; N. Ratusnu; M.S. Frola; M.C. Aparicio; B. Ríos; M.N. Anselmo; R. Hansen; S. De Filippi; C. García Dans; L. de Labra; M.A. Peche; T.M. Strella; M. Ibáñez Duran; M.B. García Rosales; M. Dirchwolf; O.A. Galdame; Adrián Gadano
Transplantation | 2012
Paola Casciato; Alejandra Villamil; J. C. Bandi; Omar Galdame; Leila Haddad; E. de Santibañes; Adrián Gadano